Retatrutide Listing Tracking: Monitoring Vendor Changes Over Time

Retatrutide listing tracking works when you sort every revision into one of three classes before you log it: specification changes (vial mg, suggested diluent volume, batch or COA), economic changes (price, stock status, shipping origin), and cosmetic changes (photos, page copy, disclaimer wording). Specification changes invalidate every figure you previously calculated from that listing. Economic changes invalidate only your cost baseline. Cosmetic changes invalidate nothing, and logging them as if they did is how tracking logs fill with noise and get abandoned.

Which listing edits matter and which are cosmetic?

The class a field belongs to determines what you have to recompute when it moves. A vial that goes from 10 mg to 5 mg breaks your cost-per-mg figure, your concentration figure, and every cross-vendor comparison you built on that page. A price that moves $5 breaks only the first of those three.

Field	Change class	What it invalidates	Recheck
Vial size (mg)	Specification	Cost per mg, concentration, all prior comparisons	Weekly
Suggested diluent volume (mL)	Specification	Concentration and per-unit figures	Weekly
COA link or batch number	Specification	Provenance of the vial you priced	Monthly
Listed price	Economic	Cost-per-mg baseline only	Weekly
Stock status or restock ETA	Economic	Ordering timing, no calculated figure	Weekly
Shipping origin or lead time	Economic	Landed cost, not unit cost	Monthly
Product photo, page copy, disclaimers	Cosmetic	Nothing; log the date seen, not the text	Quarterly

Field classification and recheck cadence used by this register. No external figures appear in this table.

Concentration is vial mg divided by mL of bacteriostatic water, so a vendor can leave “10 mg vial” untouched in the product title and still move the resulting concentration by revising the suggested volume further down the page. The worked concentration example for a revised diluent volume shows what that shift does to a per-unit figure.

What does a price revision actually cost per mg?

Log the price, then log the derived cost per mg next to it. The derived figure is what makes a revision comparable across vial sizes, and it is the number a percentage threshold can be set against.

Vial	Catalog price (USD)	Formula	Cost per mg (USD)
10 mg	100	100 ÷ 10	10.00
20 mg	195	195 ÷ 20	9.75
20 mg, per 10 mg equivalent	97.50	195 ÷ 2	9.75

Cost per mg derived from this register’s catalog reference prices as of September 2026. Each figure is the listed price divided by the vial mg; the third row divides the 20 mg price by two to express it against the smaller format.

The gap between the two formats is $10.00 − $9.75 = $0.25/mg, or 2.5% of the 10 mg rate ($0.25 ÷ $10.00 = 0.025). Buying the second 10 mg inside a 20 mg vial costs $195 − $100 = $95, which is $5 less than buying it as a separate 10 mg vial.

That 2.5% margin is thin enough to flip. The 20 mg vial stops being cheaper per mg the moment its price passes $10.00 × 20 = $200, so a $6 increase on the 20 mg format while the 10 mg format holds at $100 reverses which vial is the cheaper unit. Set your log’s alert threshold below the flip point rather than at an arbitrary round number: for these two formats, a 5% move on either price is enough to change the answer.

How often should each field be re-checked?

Match the interval to the class, not to the vendor. Weekly checks on price and vial mg, monthly on COA and shipping origin, quarterly on page copy, is a cadence one person can hold for a year across five or six sources. Daily checking produces more entries and no more signal, because specification changes do not arrive daily.

A missed check is itself worth recording. If a listing goes eight weeks without a look, the log should say so, because a change found after an eight-week gap has an eight-week window rather than a date. Guidance on how frequently vendor pages get revised helps set the floor, and the signals that a page has gone stale tell you when a listing has stopped being maintained at all, which is a different finding from a listing that changed.

What do you do when two snapshots disagree?

Record both values with both dates and keep the older snapshot file. Do not overwrite. A log that holds only the current state can tell you what a listing says and cannot tell you what it did, and the second question is the one tracking exists to answer.

Where a listing’s own fields contradict each other in the same snapshot, note the contradiction rather than picking a winner. A page whose title reads “10 mg” while its specification block reads “10 mg/vial, 5 mg/mL at 2 mL” is internally consistent; a page whose title reads “10 mg” while the specification block reads “5 mg/mL at 1 mL” is not, and that inconsistency is a log entry in its own right. The breakdown of which fields move when a page is republished covers which of these pairings tend to drift apart.

A listing that revises its stated vial mg twice in one quarter belongs in the notes column as a specification-volatility flag, separate from any price flag, because the two patterns have different causes and different consequences for anything you calculated.

What does a listing’s trial-dose claim tell you?

Some listings anchor their vial size to published trial doses. That claim is checkable. The phase 2 obesity trial of retatrutide enrolled 338 adults and randomised once-weekly subcutaneous dose arms of 1 mg, 4 mg, 8 mg and 12 mg over 48 weeks, with percentage change in body weight at 24 weeks as the primary endpoint; the 12 mg arm reached −17.5% at 24 weeks against −1.6% for placebo, per the phase 2 retatrutide obesity trial report in NEJM. None of those arms is 10 mg or 20 mg, so a 10 mg or 20 mg vial is a packaging format, not a trial dose, and a listing that conflates the two has made a claim your log can date and mark.

Program milestones are the other thing worth a dated line. The TRIUMPH program comprises four phase 3 multicentre, randomised, double-blind studies of weekly subcutaneous retatrutide against placebo in over 5,800 participants, spanning weight management, obstructive sleep apnea and knee osteoarthritis, with separate primary endpoints for each basket, as described in the TRIUMPH registrational trial design paper. Material sold under this name is for research use only, and a listing that cites a phase 3 readout as support for a format claim is pointing at a program whose results are not yet published; that claim goes in the notes column with the date you saw it, not in the specification fields.